Hims & Hers Health

Hims & Hers Health, Inc. is an American telehealth company established in 2017. The company provides prescription medications, over-the-counter medications, and personal care products.

Hims & Hers operates with a direct-to-consumer model. Consumers consult licensed healthcare professionals and access treatments and products through the company's platform. Customers pay for a consultation with a doctor to prescribe the drug along with the price of the drug itself. The company has expanded its offerings to include health solutions for both men and women, along with mental health services.

Founding, expansion, and public offering

Hims Inc. was established in 2017 by Jack Abraham, Andrew Dudum and Hilary Coles as a part of the Atomic Labs portfolio.[5][1] In January 2019, Hims raised $100 million in a Series C funding round with a pre-money valuation of $1 billion.[6][7] In the same month, Hims was launched in the United Kingdom with a catalogue limited by European regulation.[8]

Hims & Hers has a capitalisation of $US3.6 billion ($5.1 billion).[9]

Products and services

Hims initially sold erectile dysfunction treatment sildenafil and hair loss treatments such as minoxidil, biotin vitamins and DHT-blocking shampoo.[12][13][14] Hims launched Hers, a brand targeted to women, selling birth control pills and flibanserin in 2018.[5][15] In 2020, Hims launched mental health services, including anonymous group therapy.[16]

In 2024, Hims announced it would add compounded GLP-1 injections to its product portfolio, giving customers a way to access weight loss treatment. Hims claims to be able to provide them cheaper and with greater availability. However, unlike the brand name treatments, these compounded drugs are not reviewed by the FDA for safety.[17] In 2025, corporate partner Novo Nordisk pulled out of the partnership, ending the product offering.[18]

Novo Nordisk is suing Hims & Hers because it says Hims was marketing and selling “copycat” compounded semaglutide products that compete with Wegovy/Ozempic. Novo alleges patent infringement and argues the compounding approach was effectively mass production of an unapproved version, plus potentially misleading marketing claims about equivalence.[19] This led to shares dropping 48 per cent at the start of 2026.[9]

In 2025, Hims purchased a California facility to enable the production of compounded peptide medicines.[20] Following an April 2026 announcement by the FDA that peptides will be removed from Category 2 scheduling, Hims stock has increased on speculation that the company will enter the peptide market in a looser regulatory framework. [21]

Acquisitions

In June 2025, Hims & Hers acquired digital health platform ZAVA, expanding its footprint in Europe.[9]

On the 19th of February, 2026, the company announced the acquisition of Australian company, Eucalyptus Health, which runs Juniper, Pilot and Kin in a $1.6 billion deal.[9]

External links